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Abstract 
Background: Prasugrel and ticagrelor are two novel antiplatelet agents, which have been subject 
to large randomized trials to compare their efficacy with clopidogrel for patients with acute 
coronary syndrome (ACS).  
Aim: To conduct a systematic review of prasugrel and ticagrelor as alternative therapy to 
clopidogrel in patients who present with ACS undergoing PCI. 
Methods: The articles cited in this paper were searched on PubMed, MEDLINE, and Plymouth 
University’s Metalib database. The search terms used included “dual antiplatelet therapy”, 
“prasugrel”, “ticagrelor”, and “clopidogrel resistance”.  
Discussion: The main indications for the use of prasugrel based on current understanding are 
patients presenting with acute STEMI referred for primary PCI, ACS patients with DM, or those 
who have a high risk of stent thrombosis. Ticagrelor, on the other hand, may provide optimal 
benefit for patients with NSTEMI treated with conservative or invasive therapy, those with 
previous TIA or stroke, advanced age, or small body surface.  
Conclusion: Prasugrel and ticagrelor have been shown to be adequate P2Y12 antiplatelet therapy 
alternatives to clopidogrel in the management of patients with ACS. While prasugrel and 
ticagrelor have both been shown to clinically improve platelet inhibition and significantly reduce 
the incidence of stent thrombosis compared with clopidogrel therapy, both increase the risk of a 
significant bleeding incident. Both ticagrelor and prasugrel have been shown to be appropriate 
and effective treatment alternatives for ACS patients who display clopidogrel treatment 
resistance or failure. 
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The New Dual Antiplatelet 
Therapy Agents and their Role 
in Acute Coronary Syndrome 
Introduction 
The long-term outcome of stent placement 
by percutaneous coronary interventions 
(PCI) for the management of acute coronary 
syndrome (ACS) is improved significantly by 
2 key interventions: the use of high-pressure 
balloon inflations and the administration of 
periprocedural dual-antiplatelet therapy 
(DAPT). Although the benefits of DAPT as 
a medical treatment of ACS have been 
proven, its indication is obligatory in this 
setting to prevent post-stent placement 
complications, such as stent thrombosis and 
other ischaemic changes.1 The basis of this 
strategy is the suppression of thromboxane 
A2 production (by the administration of 
aspirin) and the addition of a P2Y12-receptor 
inhibitor, an agent that blocks adenosine 
diphosphate (ADP)–mediated platelet 
activation. For many years, the P2Y12-
receptor inhibitor of choice has been the 
thienopyridine clopidogrel. Clopidogrel 
combined with aspirin for 12 months has 
widely become the standard practice 
following successful management of ACS 
with PCI.2,3 
There are, however, 2 concerns when using 
clopidogrel. The first is its delayed onset of 
action, which is due to the 2-stage activation  
process involving cytochrome P450 
isoenzymes. 4  The second relates to the 
increasing evidence of a subset of patients 
that are clopidogrel hyporesponders or non-
responders, who are found to have delayed 
and/or insufficient inhibition of platelet 
function. The mechanism for this variable 
“clopidogrel resistance”, also known as 
“high on-treatment platelet reactivity 
(HTPR)”, is thought to be due to a number 
of genetic and non-genetic factors that 
affect the bioactivation of clopidogrel.5,6 An 
optimal inhibition of platelet function 
therefore cannot be guaranteed in these 
patients, especially in those who are carriers 
of the CYP2C19*2 loss-of-function 
polymorphism. 7  This phenomenon has 
commonly been associated with disastrous 
and life-threatening sequelae, including stent 
thrombosis, recurrent myocardial infarction 
(MI), and cardiovascular death.4 Although 
relatively uncommon, this phenotype 
encompasses a group of patients whereby 
clopidogrel is not able to provide adequate 
platelet suppression and for whom 
alternative treatment options are required. 
The goal of this article is to synthesize the 
most recent and relevant literature for the 
use of the antiplatelet agents prasugrel and 
ticagrelor in order to provide up-to-date 
clinical guidance of their use as alternatives 
for clopidogrel in patients who present with 
ACS undergoing PCI. 
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Methods 
The articles cited in this paper were 
reviewed for their relevance to this topic. 
Search engines used include PubMed, 
MEDLINE, and Plymouth University’s 
Metalib database. The search terms include 
“dual antiplatelet therapy”, “prasugrel”, 
“ticagrelor”, and “clopidogrel resistance”. 
Primary research articles and reviews, 
including the PLATO and TRITON TIMI-
38, were included for their relevance to this 
subject. Publications included in the search 
were in English only. Literature published 
prior to 2008 was included only if it 
provided critically relevant information, and 
the majority of papers were identified in the 
period from 2008 to present.  
Discussion  
Prasugrel 
In recent years, new P2Y12-receptor 
inhibitors have become licensed for use in 
the management of ACS. The first of these 
is prasugrel, a third-generation 
thienopyridine that irreversibly binds to the 
P2Y12 receptor.
8  Prasugrel is similar to 
clopidogrel in that it is a prodrug that 
requires bioactivation to become an active 
metabolite. However, in contrast to 
clopidogrel, which requires 2 metabolic 
steps to become its active metabolite, 
prasugrel requires only 1 metabolic step, 
which results in a faster and more consistent 
antiplatelet effect. Furthermore, prasugrel 
has been shown to function independently 
of the loss-of-function genetic variants that 
are believed to cause the wide variability in 
effectiveness of platelet inhibition seen in 
clopidogrel therapy.7 
The clinical effectiveness of prasugrel as an 
alternative antiplatelet to clopidogrel in 
patients with ACS has been extensively 
studied. In the TRITON TIMI-38 trial, 9 
over 13  000 patients with ACS were 
randomized into 2 treatment groups. One 
group received a 300  mg loading dose (LD) 
of clopidogrel followed by a maintenance 
dose (MD) of 75  mg daily for the whole 
treatment period of up to 15 months, while 
the second group received a LD of 60  mg of 
prasugrel followed by 10  mg MD over the 
same treatment period. With the exception 
of patients diagnosed with ST-segment-
elevation myocardial infarction (STEMI) in 
whom study medication was given without 
knowledge of coronary anatomy, a 
diagnostic angiogram was obligatory for 
patients before randomization. The results 
of this trial found that there was a significant 
reduction in the primary composite efficacy 
endpoint (cardiovascular mortality, non-fatal 
MI, and non-fatal stroke) by 18% in patients 
taking prasugrel compared with clopidogrel 
(9.9% vs 12.1%; p < 0.001). In addition, the 
rate of definite stent thrombosis was halved 
in the prasugrel group (0.88% vs 2.03%; p < 
0.001). These results show that the greater 
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antiplatelet potency of prasugrel is able to 
achieve a more favourable and consistent 
level of platelet function suppression and 
thus lead to significant improvements in 
clinical outcomes. 
The drawback that was anticipated with the 
increased efficacy of prasugrel was its 
increased bleeding risk. Patients taking 
prasugrel in this trial were found to have an 
increased incidence of spontaneous non-
coronary artery bypass graft (CABG)–
related major bleeding hazards compared 
with the clopidogrel group (TIMI bleeding 
classification: 2.4% vs 1.8%; p = 0.03), along 
with more frequent fatal bleedings (0.4% vs 
0.1%; p = 0.002). In particular, patients who 
underwent urgent CABG surgery were at a 
significantly higher absolute risk of 
perioperative bleeding after the intake of at 
least 1 dose of prasugrel (13.4% vs 3.2% 
respectively, p < 0.001). Other risk factors, 
such as low bodyweight (< 60 kg), old age, 
and previous cerebrovascular events, were 
also associated with unfavourable 
outcomes.10 In order to assess these 
drawbacks, a prespecified net clinical benefit 
analysis was performed (a composite of the 
primary end points and non–CABG-related 
TIMI major haemorrhage), which 
demonstrated a net clinical benefit 
associated with prasugrel therapy despite the 
excess bleeding (12.2% vs 13.9%, p = 0.004). 
However, these data clearly demonstrate 
that the benefits of improved platelet 
suppression with prasugrel therapy must be 
weighed against its increased bleeding risk, 
especially in patients who are at a greater 
risk of severe bleeding. 
Interestingly, it was found that for diabetic 
patients enrolled in the trial, prasugrel 
displayed a 28% relative risk reduction (RRR) 
of the primary composite endpoint to a 
statistically significant extent (12.2% vs 
17.0%, p < 0.001) compared with non-
diabetics (9.2% vs 10.6%, p = 0.02, RRR 
13.0%).10 Diabetics who were treated with 
prasugrel in this trial were found to have a 
reduced incidence of MI during the follow 
up period of 40% (p < 0.001). While the rate 
of severe TIMI bleedings was increased in 
prasugrel- vs clopidogrel-treated non-
diabetics (2.4% vs 1.6%, p = 0.02), it was 
comparable between prasugrel- and 
clopidogrel-treated diabetics (2.6% vs 2.5%, 
p = 0.81). Therefore, it appears that 
prasugrel may be able to provide further 
benefit to diabetic patients who present with 
ACS, which could result in more favourable 
clinical outcomes. 
Ticagrelor 
Whilst clopidogrel and prasugrel are both 
thienopyridines and prodrugs that require 
metabolic activation, ticagrelor, an orally 
administered cyclopentyl-triazolo-pyrimidine, 
is a directly active compound which binds 
reversibly to the P2Y12 receptor.
11 Similar to 
prasugrel, ticagrelor has a faster onset of 
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action than clopidogrel and provides 
stronger and more consistent platelet 
inhibition. Due to its reversibility of action 
and short half-life (7–8.5 hours, which is 
similar to the active metabolite of prasugrel: 
7.4 hours), a LD of 180  mg and MD of 
90  mg twice daily is needed to achieve 
constant platelet inhibition over time. In 
contrast to clopidogrel, ticagrelor has been 
shown to have no variability in efficacy due 
to genetic factors.12 
The benefit of ticagrelor therapy compared 
with clopidogrel in preventing 
cardiovascular events in ACS patients has 
been evaluated through the PLATO 
(platelet inhibition and patient outcomes) 
trial, a multicentre, double-blind, 
randomized phase-3 trial including over 
18  000 patients with ACS (non–ST-segment 
elevation and ST-segment elevation). 13  In 
this trial, patients were randomized 
regardless of which treatment approach was 
chosen (interventional, primarily 
conservative, or conservative only) to either 
the doses detailed above or clopidogrel 
starting with a LD of 300–600  mg followed 
by a 75  mg daily MD over the full study 
duration. The results of this trial 
demonstrated that ticagrelor therapy 
reduced the rate of the primary endpoint 
(death from vascular causes, non-fatal MI, 
or non-fatal stroke) at 12 months (9.8% vs 
11.7%, p < 0.001). Patients treated with 
ticagrelor also experienced a reduction in 
definite or probable stent thrombosis (2.2% 
vs 3.0%, p = 0.014). This evidence therefore 
demonstrates very clear clinical benefit in 
the use of ticagrelor over clopidogrel in ACS 
patients. 
By using the study-specific protocol of 
severe bleeds including perioperative 
CABG-related bleedings, no statistically 
significant differences were demonstrated 
between the 2 treatment groups (11.6% for 
ticagrelor vs 11.2% for clopidogrel, p < 
0.43). However, the rate of non-CABG 
major bleeding was increased significantly 
with ticagrelor when the PLATO (4.5% vs 
3.8%, p = 0.03) and TIMI criteria (2.8% vs 
2.2%, p = 0.025%) were applied to these 
results. In addition, although fatal 
intracranial bleeding was significantly more 
frequent in the ticagrelor treatment arm 
(0.1% vs 0.01%), overall PLATO-defined 
fatal bleeding was not significantly different 
between the 2 treatment groups (0.3% vs 
0.3%, p = 0.66). Of note, the benefit of 
ticagrelor was shown to be consistent across 
different subgroup analyses, such as patients 
with an initial conservative approach with 
non-invasive therapy, patients undergoing a 
planned invasive strategy, and also patients 
undergoing CABG.14-15  
A number of non-haematological safety 
endpoints have been observed in ticagrelor, 
including higher rates of dyspnoea and 
ventricular pauses, and increased levels of 
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creatinine and uric acid during treatment 
compared with clopidogrel. The exact 
mechanism for ticagrelor-related dyspnoea 
remains unproven, with no cardiac or 
pulmonary pathology observed.16 A number 
of observations from preliminary data have 
led to the hypothesis that adenosine may 
play a role in this presentation. Ticagrelor 
has been observed to inhibit adenosine 
uptake into erythrocytes by increasing 
circulating levels of adenosine with a 
theoretical effect similar to that of 
intravenous adenosine administration. This 
results in changes to regional blood flow as 
observed with dipyridamole, which is also 
an inhibitor of adenosine uptake.17-18 In a 
study by Burki et al., 19  the intravenous 
infusion of adenosine into healthy 
volunteers induced dyspnoea without any 
associated bronchoconstriction. This 
thereby led to the likelihood that the 
adenosine-induced dyspnoea is due to the 
stimulation of lung receptors, such as vagal 
C-fibres. The hypothesis may also account 
for the increased incidence of ventricular 
pauses, as adenosine administration can 
induce sinus bradycardia by producing an 
atrioventriuclar node block. 20  Although 
these side effects have been associated with 
higher discontinuation rates, they have not 
shown any significant clinical impact. 
Therefore, although ticagrelor has been 
shown to increase the bleeding risk of 
patients when compared with clopidogrel, 
its use has not increased the rate of overall 
severe non-haematological clinical events. 
The use of ticagrelor over clopidogrel 
therapy has been studied in a number of 
prespecified patient subgroups. Of 
significant importance is ticagrelor’s 
demonstrated reduction in primary 
combined endpoint in patients undergoing 
CABG within 7 days after the last study 
drug intake. The total mortality, 
cardiovascular death, and non-
cardiovascular death were all significantly 
reduced in ticagrelor patients (p < 0.01, p < 
0.01, p = 0.07 respectively), while the 
bleeding risk was similar between the 
treatment regimens.15 Additionally, ticagrelor 
was especially effective in patients with 
chronic kidney disease (CKD; creatinine 
clearance < 60 mL/minute), where it 
achieved a RRR of the primary combined 
endpoint of 21% over clopidogrel (17.3% vs 
22%), which was more pronounced than in 
patients with normal renal function (RRR 
11%, 7.9% vs 8.9%).21 Therefore, in light of 
the reported benefits within these subgroup 
analyses, the use of ticagrelor should 
especially be considered in certain ACS 
patients, such as those undergoing CABG or 
those with a history of CKD. 
Current guidelines and further considerations 
Due to the significant results of both the 
TRITON TIMI-38 and PLATO trials, both 
prasugrel and ticagrelor now appear in the 
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current European guidelines for non–ST-
elevation ACS and myocardial 
revascularization.2, 22 The new guidance for 
patients with either STEMI or non-ST 
eleveation myocardial infarction (NSTEMI) 
referred for primary PCI (PPCI) now 
recommends both of the new agents as 
preferred choices over clopidogrel (IB class 
recommendation for prasugrel and ticagrelor 
vs IC for clopidogrel). While ticagrelor is 
recommended for all patients with NSTEMI 
regardless of the initial treatment strategy, 
prasugrel is only recommended for patients 
once the coronary anatomy has been imaged 
and for those who are undergoing PCI as 
per the TRITON TIMI-38 trial design. 
According to the new European guidelines, 
clopidogrel should now only be used in ACS 
patients in cases where there are clear 
contraindications against the newer agents 
or if neither are available, and may be 
considered in elderly patients or those with a 
high bleeding risk. In patients with stable 
coronary artery disease and planned PCI, 
clopidogrel remains the agent of choice. In 
patients due to undergo non-emergency 
major surgery (including CABG), prasugrel 
should be discontinued 7 days before the 
procedure, and ticagrelor and clopidogrel 
should be discontinued 5 days before. 
Due to the positive outcomes reported from 
the TRITON TIMI-38 trial and the change 
in international guidance on the 
management of patients with ACS and 
subsequent support from the National 
Institute of Health and Care Excellence 
(NICE),23 prasugrel has been taken up as the 
default P2Y12 inhibitor in over half of the 
units providing PPCI services in the UK. 
However, there have been doubts over this 
shift in clinical practice for a number of 
reasons. Firstly, there were criticisms of the 
primary efficacy endpoint used in the 
TRITON TIMI-38 being poorly defined.24 
Prasugrel has been shown to significantly 
reduce the incidence of non-fatal MI when 
compared with clopidogrel (7.3% vs 9.5%, p 
< 0.001). However, when taking into 
account the rates of cardiovascular death 
between the 2 treatment groups, it was 
found to be 2.4% and 2.1% respectively (p = 
0.31%). Also, the rate of both fatal and non-
fatal stroke between the 2 groups were 
found to be 1.0% and 1.0% (p = 0.93). 
While it cannot be disputed that there is a 
significant reduction in the incidence of 
stent thrombosis in patients receiving 
prasugrel compared with clopidogrel (1.1% 
vs 2.4% respectively, p < 0.0001), it may be 
argued that the reduction in non-fatal MI 
cannot justify the excess rates of fatal MI 
and severe bleeding incurred by this change. 
Similarly, there is a perceived drive to 
prescribe ticagrelor for either PPCI or for all 
ACS patients in the wake of data procured 
from the PLATO trial, which is supported 
by recent NICE guidance.25 However, there 
are concerns raised over the data for 
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ticagrelor therapy produced by this trial. 
One that has already been discussed is the 
increased bleeding rate found in patients 
who did not undergo CABG when 
compared with the clopidogrel treatment 
regime, when applying either PLATO study 
bleeding definitions or TIMI major bleeding 
criteria (p = 0.03). Another refers to the 
PLATO PPCI subgroup analysis, 26  which 
found that the rate of primary endpoint was 
not found to be significantly different 
between the ticagrelor treatment group and 
the clopidogrel group, although there was a 
trend in favour of the former. There was 
also no significant difference found in 
mortality rates between the 2 treatment arms. 
In light of this analysis, it appears that the 
evidence that has been presented for the 
benefit of ticagrelor over clopidogrel may 
not be as robust as initially thought. 
Therefore, further clinical data may be 
required to assuage the concerns that have 
emerged over the replacement of 
clopidogrel with either prasugrel or 
ticagrelor. 
A particular issue that has raised significant 
concerns as a result of the PLATO trial is 
the effect of geographical variation on the 
effectiveness of ticagrelor. It was noted that 
in North America, clopidogrel was 
associated with a better outcome trend than 
ticagrelor, whereas the reverse was true in 
the rest of the world (ROW), with a hazard 
ratio (HR) of 1.25 in North America 
compared with the HR of 0.84 overall. 27 
Although the United States and the ROW 
displayed similar data quality and trial 
conduct, it was discovered that the median 
maintenance dose of aspirin, which was 
decided at the discretion of each centre, 
varied significantly between the 2 subgroups. 
It was observed that on discharge, patients 
in North America were more likely to be 
receiving high-dose maintenance aspirin, 
whereas patients who were discharged from 
the ROW were more likely to be receiving 
low-dose maintenance aspirin. When 
analysed, this discrepancy may have 
accounted for between 80% to 100% of the 
observed regional interaction. A similar 
geographical trend in high maintenance dose 
of aspirin was observed in the TRITON-
TIMI 38 trial, with 66% of patients in North 
America receiving high-dose aspirin 
compared with only 28% in the ROW, with 
an odds ratio of 5.19 (95% CI: 4.72–5.70; p 
< 0.001).28 Despite this significant difference 
between the 2 subgroups, there was no 
modification of the clinical effect of 
prasugrel versus clopidogrel based on 
discharge aspirin dose with respect to the 
primary efficacy endpoint (HR 
CVD/MI/stroke = 0.78 [95% CI: 0.64%– 
0.95%] for aspirin < 150 mg; HR 
CVD/MI/stroke = 0.87 [95% CI: 0.69– 
1.10] for aspirin > 150 mg; p = 0.48).  
There is currently no definitive biological 
explanation for this occurrence, although 
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there are several potential hypotheses to 
explain why aspirin doses may modulate the 
efficacy of ticagrelor. Aspirin exerts an 
antithrombotic effect by the inhibition of 
platelet cyclooxygenase, which in turn 
reduces thromboxane A2 release and 
additionally inhibits endothelial release of 
prostacyclin in a dose-dependent fashion at 
daily doses exceeding 80  mg.29 Prostacyclin 
reduces platelet reactivity and may 
synergistically contribute to the antiplatelet 
effects of P2Y12 inhibitors in vivo, which 
results in the therapeutic effects of a higher 
mean level of P2Y12 inhibition.
30  The 
therapeutic effects of a higher mean level of 
P2Y12 inhibition may be attenuated when 
endogenous prostacyclin production is 
inhibited. However, due to the absence of a 
clear pathological process, the possibility 
that this is the result of chance alone 
remains a reasonable consideration. 
However, there is a possible trend observed 
in high-dose maintenance aspirin with 
poorer clinical outcomes when given with 
ticagrelor. Therefore, in conjunction with 
the results from this analysis and current 
guideline recommendations, the use of low-
dose maintenance aspirin is likely to be 
associated with the most favourable 
outcomes with ticagrelor administration. 
A final consideration in this article is the 
comparison between prasugrel and 
ticagrelor as to which is the most effective 
antiplatelet agent. Currently, there is no trial 
that directly compares the 2 agents for the 
management of ACS patients, which makes 
much of the potential differences between 
the two unresolved. Additionally, due to the 
varying study designs of the TRITON 
TIMI-38 and PLATO trials, it is not 
possible to extrapolate the results for a 
definitive comparison. Despite these 
limitations, there are a number of simple 
comparisons between prasugrel and 
ticagrelor which can be drawn from these 2 
studies. Firstly, while the benefit of 
prasugrel in the TRITON TIMI-38 trial was 
exclusively attributed to the reduced rate of 
non-fatal MI of 89 patients, ticagrelor’s 
reduction on mortality in PLATO of 107 
deaths clearly represents a major clinical 
outcome difference between the 2 trials. As 
previously discussed, both prasugrel and 
ticagrelor have been shown to significantly 
reduce the incidence of stent thrombosis 
compared with clopidogrel. The number 
needed to treat (NNT) for prasugrel was 
calculated to be 77 for preventing stent 
thrombosis, whereas the NNT for ticagrelor 
was 143. These results may therefore 
advocate the use of prasugrel over ticagrelor 
in patients with a higher risk of developing 
stent thrombosis (e.g. those with diabetes 
mellitus (DM) and small stent diameter). 
Another important consideration is that 
while both medicines lowered the rate of the 
primary and secondary endpoints in patients 
with DM compared with clopidogrel, the 
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NNT for DM patients taking prasugrel was 
21 compared with 48 for ticagrelor. One 
may therefore favour the use of prasugrel 
over ticagrelor for patients with DM who 
present with ACS and are intended for PCI. 
With regard to the different ACS subsets, 
there seems to be a significant benefit for 
the use of prasugrel rather than ticagrelor in 
STEMI patients (NNT 42 vs 71 
respectively). On the other hand, ticagrelor 
was shown to reduce the primary endpoint 
for NSTEMI patients, but not for those 
with unstable angina, whereas prasugrel had 
an effect on both. This reduction in 
mortality may favour prasugrel 
administration for patients who present with 
STEMI and ticagrelor for NSTEMI patients.  
In terms of side effects, both therapies have 
been found to similarly increase the risk of 
non–CABG-related TIMI major bleeding 
events compared with clopidogrel. However, 
CABG-related TIMI major bleedings were 
significantly more prevalent in prasugrel 
than ticagrelor. In addition, patients who 
have high risk characteristics where 
prasugrel is contraindicated, such as a 
history of transient ischaemic attack (TIA) 
or stroke, age > 75 years, body weight of < 
60 kg, ticagrelor therapy may be more 
suitable. As discussed above, the side effects 
of ticagrelor administration of dyspnoea and 
ventricular pauses, which are seldom seen in 
prasugrel administration, may be a cause for 
concern in terms of drug discontinuation, 
along with the fact that ticagrelor is 
administered twice daily as opposed to once 
daily in the case of prasugrel. Additionally, 
there are concerns over the increased rate of 
cancer, especially in women, with prasugrel 
therapy in TRITON TIMI-38 compared 
with clopidogrel. In a review of the 
TRITON TIMI-38 trial by Floyd JS et al.,31 it 
was found that 92 patients had new solid 
tumours in the prasugrel treatment arm 
(1.4%) as opposed to 64 in the clopidogrel 
arm (0.9%) with a HR of new and worse 
solid cancers of 1.44 (p = 0.02). Currently, 
the underlying mechanism of this trend is 
unclear and no association has previously 
been made between other antiplatelet drugs 
such as aspirin, clopidogrel, and ticagrelor 
with an increased risk of new or worsening 
neoplasms. However, this matter is worth 
noting when considering the long-term use 
of prasugrel, and further research must be 
undertaken.  
In short, the main indications for the use of 
prasugrel based on current understanding 
are patients presenting with acute STEMI 
referred for primary PCI, ACS patients with 
DM, or those who have a high risk of stent 
thrombosis. Ticagrelor, on the other hand, 
may provide optimal benefit for patients 
with NSTEMI treated with conservative or 
invasive therapy, those with previous TIA or 
stroke, advanced age, or small body surface. 
Additionally, by indirectly comparing the 
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PLATO and TRITON TIMI-38 trials, one 
may infer the superiority of ticagrelor to 
prasugrel for chronic preventative use when 
taking into account its absolute mortality 
reduction, reduced haemorrhagic fatalities, 
and less CABG-related bleeding, as well as a 
lack of cancer risk. This may therefore 
suggest that the optimal treatment regimen 
would be prasugrel prescribed for the first 
30 days due to its clear clinical benefit in the 
early stages of treatment, and then switched 
to ticagrelor after 30 days due to its potential 
superiority in achieving favourable long-
term outcomes. However, further study is 
needed in order to ascertain whether this 
tandem strategy of prasugrel and ticagrelor 
would be safe and effective in providing an 
overall clinical benefit in comparison to each 
medication on its own. 
Conclusion 
Prasugrel and ticagrelor have been shown to 
be adequate P2Y12 antiplatelet therapy 
alternatives to clopidogrel in the 
management of patients with ACS. The 
results of the TRITON TIMI-38 and 
PLATO trials have provided a significant 
insight into the benefits and drawbacks of 
the use of both agents. While prasugrel and 
ticagrelor have both been shown to clinically 
improve platelet inhibition and significantly 
reduce the incidence of stent thrombosis 
compared with clopidogrel therapy, both 
increase the risk of significant bleeding 
incidents. This is particularly the case in 
patients with risk factors such as low body 
weight, advanced age (>75 years old), or 
those that are due to undergo CABG. There 
are certain subgroups of ACS patients that 
have been especially shown to benefit from 
these new agents. Prasugrel has been shown 
to improve clinical outcomes in diabetic 
ACS patients compared with non-diabetic 
ACS patients, and ticagrelor has 
demonstrated beneficial outcomes for ACS 
patients who are due to undergo CABG or 
have a history of CKD. There are some 
doubts over the data from both trials which 
suggest that prasugrel and ticagrelor are 
overall superior treatments to clopidogrel, 
hence further study is required to confirm 
this. However, there are a number of 
limitations with clopidogrel use that both of 
these new agents are not susceptible to, such 
as a delayed onset of action and a wide 
variability in efficacy. Both ticagrelor and 
prasugrel have been shown to be 
appropriate and effective treatment 
alternatives for ACS patients who display 
clopidogrel treatment resistance or failure. 
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Learning Points 
What is  a lready known 
• The use of clopidogrel in conjunction with aspirin for patients with acute coronary 
syndromes (ACS) has come under scrutiny due to evidence of its varying levels of 
efficacy, with reports of severe and sometimes fatal outcomes. 
• Two novel antiplatelet agents, prasugrel and ticagrelor, have undergone large 
randomized trials to compare their efficacy to clopidogrel in the TRITON TIMI-
38 and PLATO trials respectively.  
What this  s tudy adds 
• In an indirect comparison of the PLATO and TRITON TIMI-38 trials, ticagrelor 
is shown to have the greater overall clinical benefit with significantly reduced 
mortality. 
• The main indications for prasugrel use is for patients with acute STEMI, ACS 
patients with DM, and patients at high risk of stent thrombosis.  
• The main indications for ticagrelor use is for patients with NSTEMI, patients with 
a history of CKD, and in those where prasugrel is contraindicated. 
• Both agents have demonstrated a more consistent antiplatelet effect than 
clopidogrel and have shown to be effective alternatives for patients who are non-
responsive to clopidogrel therapy. 
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